Nonspecific interstitial pneumonia revealing an antisynthetase syndrome

Image by <a href="https://pixabay.com/users/kalhh-86169/?utm_source=link-attribution&utm_medium=referral&utm_campaign=image&utm_content=944557">kalhh</a> from <a href="https://pixabay.com//?utm_source=link-attribution&utm_medium=referral&utm_campaign=image&utm_content=944557">Pixabay</a>
Submitted: August 6, 2021
Accepted: October 12, 2022
Published: November 29, 2022
Abstract Views: 731
PDF: 157
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

One of the most common interstitial lung diseases in antisynthetase syndrome is nonspecific interstitial pneumonia (NSIP). A 49-year-old woman presented with slow progression exertional dyspnea, myalgia, and arthralgia. The radiological findings indicated an NSIP pattern. Autoantibodies were found to be positive, but no lung biopsy was performed. Even though corticosteroid therapy significantly improved the patient's dyspnea, the patient developed mechanic's hands, the anti-synthetase antibody (PL12) became positive, and creatine phosphokinase (CPK) levels increased. As a result, the antisynthetase syndrome was established. The patient follow-up after three years revealed an improvement in symptoms under corticosteroid therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Dobashi N, Fujita J, Ohtsuki Y, and al. Detection of anti-cytokeratin 8 antibodies in the serum of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis associated with collagen vascular disorders. Thorax 1998;53:969–74. DOI: https://doi.org/10.1136/thx.53.11.969
Dobashi N, Fujita J, Murota M, and al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti- cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000;178:171–9. DOI: https://doi.org/10.1007/s004080000020
Fujita J, Dobashi N, Ohtsuki Y, and al. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 1999;177:3119-9. DOI: https://doi.org/10.1007/PL00007649
Fujita J, Ohtsuki Y, Yoshinouchi T, et al. Idiopathic non-specific interstitial pneumonia: as an “autoimmune interstitial pneumonia”. Respir Med 2005;99:234-40. DOI: https://doi.org/10.1016/j.rmed.2004.07.001
Arakawa H, Yamada H, Kurihara Y, and al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003;123:1096–103. DOI: https://doi.org/10.1378/chest.123.4.1096
Yamadori I, Fujita J, Bandoh S, and al. Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjogren’s syndrome. Rheumatol Int 2002;22:89–92. DOI: https://doi.org/10.1007/s00296-002-0204-0
Cavagna L, Nuno L, Scire CA, and al. Clinical spectrum time course in anti Jo-1 positive anti-synthetase syndrome. Medicine (Baltimore) 2015;94:e1144.
Alfraji N, Mazahir U, Chaudhri M, Miskoff J. Anti-synthetase syndrome: a rare and challenging diagnosis for bilateral ground-glass opacities - a case report with literature review. BMC Pulm Med 2021;21:11. DOI: https://doi.org/10.1186/s12890-020-01388-0
Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken) 2013;65:800-8. DOI: https://doi.org/10.1002/acr.21895
Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol 2020;10:101503. DOI: https://doi.org/10.1016/j.berh.2020.101503
Todd NW, Marciniak ET, Sachdeva A, et al. Organising pneumonia/nonspecific interstitial pneumonia overlap is associated with unfavorable lung disease progression. Respir Med 2015;109:1460-8. DOI: https://doi.org/10.1016/j.rmed.2015.09.015
Belloli E, Beckford R, Hadley K, Flaherty KR. Idiopathic non-specific interstitial pneumonia. Respirology 2016;21;259-68. DOI: https://doi.org/10.1111/resp.12674
Bondue B, Leduc D, Froidure A, et al. Usefulness of surgical lung biopsies after cryobiopsies when pathological results are inconclusive or show a pattern suggestive of a nonspecific interstitial pneumonia. Respir Res 2020;21:231. DOI: https://doi.org/10.1186/s12931-020-01487-w
Sumikawa H, Johkoh T, Fujimoto K, et al. Pathologically proved nonspecific interstitial pneumonia: CT pattern analysis as compared with usual interstitial pneumonia CT pattern. Radiology 2014;272:549-56. DOI: https://doi.org/10.1148/radiol.14130853
Cabon M, Meyer A, Hervier B. [Rôle phénotypique des anticorps anti-Ro52 (TRIM21) dans le syndrome des anti-synthétases (étude RoSAS): marqueur prédictif de sévérité?].[Article in French]. Rev Med Interne 2017;38:A79-A80. DOI: https://doi.org/10.1016/j.revmed.2017.03.071
Rüegg CA, Maurer B, Laube I, et al. Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab. BMJ Case Rep 2019;12:e231006. DOI: https://doi.org/10.1136/bcr-2019-231006

How to Cite

Moussa , Nedia, Rahma Gargouri, Mouna Snoussi, Rym Khemakhem, Zouhir Bahloul, and Samy Kammoun. 2022. “Nonspecific Interstitial Pneumonia Revealing an Antisynthetase Syndrome”. Monaldi Archives for Chest Disease 93 (3). https://doi.org/10.4081/monaldi.2022.2045.